Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
3,290 results
  • Management of Buerger's Disease in Endovascular Era. [Journal Article]
    Int J Angiol 2019; 28(3):173-181Ghoneim BM, Karmota AG, … Khairy HM
  • This study was aimed to report data on the feasibility, safety, and effectiveness of endovascular procedures in a thromboangiitis obliterans diagnosed patients presenting with critical limb ischemia (CLI). Prospective study conducted on patients affected by Buerger's disease who presented to our center along 2 years. Clinical, radiological, and patient-based outcomes were recorded at 3, 6, and 12…
  • Botany, traditional uses, phytochemistry, pharmacology and toxicology of Ilex pubescens Hook et Arn. [Review]
    J Ethnopharmacol 2019; 245:112147Jiang S, Cui H, … Zhao Z
  • CONCLUSIONS: This review summarizes the results from current studies of I. pubescens, which is one of the valuable medicinal sources from traditional herbs. Some conventional uses have been evaluated by pharmacological investigation. In addition, unresolved issues include molecular mechanisms underlying bioactivities, pharmacokinetics, toxicology and efficacy, which are still being studied and explored before achieving integration into clinical medicines.
  • Angiogenesis induction in Buerger's disease: a disease management double-edged sword? [Letter]
    Orphanet J Rare Dis 2019; 14(1):189Fazeli B, Keramat S, … Taheri H
  • Due to unknown aetiology of Thromboangiitis obliterans (TAO), its effectively treating is challenging. However, angiogenesis induction is one of the acceptable treatments for TAO patients. Recently, we have noticed that TAO patients who were under long-term treatment with angiogenesis-inducing medication showed considerable improvement in terms of healing chronic ulcers over the course of one to …
  • Unexpected inflammation in the sympathetic ganglia in thromboangiitis obliterans: more likely sterile or infectious induced inflammation? [Journal Article]
    Clin Mol Allergy 2019; 17:10Mousazadeh B, Sharebiani H, … Fazeli B
  • CONCLUSIONS: It appears that the inflammation in the SG of TAO patients is more likely a sterile inflammation, and its trigger may be mitochondrial DNA (mtDNA). Cadmium in cigarettes could be responsible for the induction of mtDNA release to the cell cytoplasm. In addition, the high expression of HMGB1 may play a role in the pathogenesis of TAO and may be responsible for both clinical manifestation of the disease and the imaging findings. Moreover, HMGB1 may be a target for treatment protocols for TAO. Further studies are highly recommended.
  • StatPearls: Bosentan [BOOK]
    StatPearls Publishing: Treasure Island (FL) Masarweh Omar M. OM Kern Medical Center Bhardwaj Abhishek A University of Pennsylvania BOOK
  • Bosentan is FDA approved for the treatment of patients with pulmonary arterial hypertension (PAH) with significant physical limitations to increase their exercise ability and decrease the rate of clinical worsening.[1][2][3] There are several non-FDA approved uses of bosentan for the treatment of idiopathic or congenital PAH in the pediatric population ages 3 years and older.[4] New studies have …
  • Molecular mechanisms regulating immune responses in thromboangiitis obliterans: A comprehensive review. [Review]
    Iran J Basic Med Sci 2019; 22(3):215-224Shapouri-Moghaddam A, Saeed Modaghegh MH, … Tavakol Afshari J
  • Thromboangiitis obliterans (TAO) is a thrombotic-occlusive as well as an inflammatory peripheral vascular disease with unknown etiology. Recent evidence has supported the immunopathogenesis of the disease, however, the factors contributing to the altered immune function and vascular tissue inflammation are still unclear. This review was intended to collate the more current knowledge on the regula…
New Search Next